

### **Amendments to the Specification**

Please add the priority information paragraph to the specification by inserting the following new paragraph before the first line of the specification:

This application is a 371 of International Application No. PCT/EP03/008568, filed 31 July 2003.

An Abstract on a separate sheet is attached as required under 37 CFR 1.72(b). Please insert the attached abstract, following the claims.

Please add the following paragraph on page 3, at line 33:

### **BRIEF DESCRIPTION OF THE DRAWINGS**

Fig. 1 illustrates a schematic of L3 and L2 immunotypes (H44/76, MC58 strains).

Fig. 2 illustrates a schematic of L3 and L1 immunotypes (126E strain).

Fig. 3 illustrates the following graphs: (A) anti-L3 LOS ELISA, (B) serum bactericidal assays, and (C) LOS depletion.

Fig. 4 illustrates the following graphs: (A) Dilution of MAb 1B2-1B7 and (B) Dilution of MAb L3.7.9.

Fig. 5 illustrates the following graphs: (A) B1820 DOC 0.1% - antigenicity with MAb L379, (B) B1820 DOC 0.1% - antigenicity mice sera raised against B1820 DOC 0.5%, and (C) B1820 DOC 0.1% - antigenicity mice sera raised against B1820 DOC 0.1%.

Fig 6 illustrates the following graphs: (A) anti-LNnT ELISA (IgG) – 14Post III – AI(OH)<sub>3</sub> and (B) anti-LNnT ELISA (IgG) – 14Post III – AI(OH)<sub>3</sub> + MPL.